Traitements antiangiogéniques dans le cancer du poumon
作者： O. -N. Pagès , J. -F. Morère
DOI: 10.1007/978-2-287-71655-3_8
关键词:
摘要: Aujourďhui le cancer du poumon est la cause plus importante de mortalite par chez ľhomme en Europe (28 000 deces annuels France) et Amerique Nord (1). Il generalement diagnostique apres longues annees ďexposition a des facteurs carcinogenes, au premier rang desquels se trouve tabac. Ainsi depit campagnes intensives lutte contre tabagisme, ses effets devastateurs vont continuer ďaugmenter dans les quinze prochaines (notamment fait ľaugmentation tabagisme feminin) (2). Par ailleurs majorite patients n’est pas eligible pour une chirurgie lors diagnostic (3) traitements conventionnels chimiotherapie n’ont guere ameliore leur survie ces 25 dernieres (4).
springer.com
sci-hub.st 参考文章(43)
JV Heymach, BE Johnson, D Prager, E Csada, J Roubec, M Pesek, I Spasova, J Hou, S Kennedy, RS Herbst, None, A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results Journal of Clinical Oncology. ,vol. 24, pp. 7016- 7016 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7016
R. B. Natale, D. Bodkin, R. Govindan, B. Sleckman, N. Rizvi, A. Capo, P. Germonpré, P. Stockman, S. Kennedy, M. Ranson, ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial Journal of Clinical Oncology. ,vol. 24, pp. 7000- 7000 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7000
T. C. Gauler, B. Fischer, J. Soria, V. Gounant, F. Griesinger, H. Krissel, D. Laurent, W. E. Eberhardt, Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. ,vol. 24, pp. 7195- 7195 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7195
Le Chiare F, Yodice A, Cancer of the lung La Semana médica. ,vol. 104, pp. 7- 9 ,(1954)
J Oan H. S Chiller, C Handra P. B Elani, J Ames K Rook, C Orey L Anger, J Unming Z Hu, D Avid H. J Ohnson, D Avid H Arrington, A Lan S Andler, COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER ,(2002)
Maurice Bariéty, Les carcinomes bronchiques primitifs Masson. ,(1967)
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Antonio Rossi, Cesare Gridelli, Emilio Bria, None, Thalidomide in Small-Cell Lung Cancer: Is It a Tombstone? Journal of Clinical Oncology. ,vol. 26, pp. 160- 160 ,(2008) , 10.1200/JCO.2007.14.6951
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287